ALZHEIMER’S ASSOCIATION® MOURNS THE DEATH OF RESEARCHER, DALE SCHENK, PH.D.

CHICAGO, October 3, 2016 -- The Alzheimer's Association is saddened to learn of the death of scientist Dale Schenk, Ph.D., who devoted his career to researching brain diseases such as Alzheimer’s and Parkinson’s. The Alzheimer's Association extends sincere condolences to Schenk’s family, friends and colleagues.

Through his research with Athena Neurosciences, Elan Pharmaceuticals and Prothena Biosciences, Schenk was pioneer in the investigation of therapies that engage the immune system to fight Alzheimer’s, Parkinson’s and other diseases. These are currently the most advanced potential treatments for Alzheimer’s. Beyond his own achievements, Schenk’s work motivated others to create a multitude of experimental drugs, many of which remain in development.

Schenk was Prothena’s President and Chief Executive Officer since 2012. From 2008-2012, he was Executive Vice President and Chief Scientific Officer of Elan, where he led research and development. From 1996-2008, Schenk held various other positions at Elan. He helped start Athena Neurosciences, Inc., which was acquired by Elan in 1996.

A humble and generous man, Schenk was a founding member of the Alzheimer’s Association Research Roundtable, and served as its first Chair from 2004 through 2010. The Research Roundtable brings together top industry scientists with leading researchers and regulators from around the world to facilitate the development of new treatments for Alzheimer's by collectively addressing obstacles to research and clinical care.

Alzheimer's Association®
The Alzheimer's Association is the leading voluntary health organization in Alzheimer's care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer's. For more information, visit alz.org.

# # #